Sarepta Therapeutics Inc., which used to be known as AVI BioPharma Inc., said a study of its eteplirsen treatment for patients with Duchenne muscular dystrophy (DMD) showed a "significant clinical benefit."
Shares in Bothell-based Sarepta (NASDAQ: SRPT) soared in early Tuesday trading, rising 113 percent, or up $3.92 to $7.38 per share.
"The magnitude of this clinical benefit is an unprecedented treatment effect in DMD. This result represents a major advance in the pursuit of a disease modifying…
Sarepta Therapeutics Inc., which used to be known as AVI BioPharma Inc., said a study of its eteplirsen treatment for patients with Duchenne muscular dystrophy (DMD) showed a "significant clinical benefit."
Shares in Bothell-based Sarepta (NASDAQ: SRPT) soared in early Tuesday trading, rising 113 percent, or up $3.92 to $7.38 per share.
"The magnitude of this clinical benefit is an unprecedented treatment effect in DMD. This result represents a major advance in the pursuit of a disease modifying…
